Related Experiment Video

Updated: Jul 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

The role of Src in prostate cancer

K Fizazi1

  • 1Department of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France. fizazi@igr.fr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 12, 2007
PubMed

Insights

Src family kinases (SFKs) drive prostate cancer progression and bone metastasis. Inhibiting SFKs, like with dasatinib, shows therapeutic potential for advanced prostate cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Src family kinases (SFKs) are critical for cellular functions and implicated in cancer development.
  • Aberrant SFK activity is linked to prostate cancer progression, including invasion and migration.
  • SFKs play a role in bone biology, relevant to prostate cancer bone metastases.

Purpose of the Study:

  • To review the role of SFKs in prostate cancer.
  • To evaluate SFK inhibition as a therapeutic strategy for prostate cancer.
  • To highlight dasatinib as a promising SFK inhibitor for prostate cancer.

Main Methods:

  • Review of existing literature on SFKs in prostate cancer.
  • Analysis of in vitro data for SFK inhibitors, particularly dasatinib.
  • Examination of clinical trial data for SFK inhibitors.

Main Results:

  • SFK overexpression is observed in prostate cancer cell lines and tissues.
  • Src inhibition reduces prostate cancer cell proliferation, invasion, and migration.
  • Dasatinib demonstrates broad in vitro efficacy against SFKs and other kinases.

Conclusions:

  • SFK inhibition is a potential therapeutic strategy for various stages of prostate cancer.
  • Dasatinib shows promise for prostate cancer treatment, with ongoing clinical evaluation.
  • Targeting SFKs may address androgen-independent growth and bone metastasis in advanced prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...